Navigation Links
Daiichi Sankyo, Inc. Awarded Prestigious NCQA Certification for National Under Pressure(TM) Hypertension Management Program
Date:12/15/2008

PARSIPPANY, N.J., Dec. 15 /PRNewswire/ -- Daiichi Sankyo, Inc., announced today that Under Pressure(TM), its national hypertension disease management program developed in accordance with JNC-7 guidelines, has received Disease Management Program Design Certification from the National Committee for Quality Assurance (NCQA), a private, not-for-profit organization dedicated to improving health care quality. NCQA certification signifies that the Under Pressure program has passed a rigorous review and successfully meets objective, evidence-based, high standards of health care quality.

"In addition to offering highly effective treatments in cardiovascular care, we are committed to ensuring that consumers have access to high quality, practical tools to help them take the best possible care of their hearts and bodies," said Kevin McDermott, Vice President, Managed Markets, Daiichi Sankyo, Inc. "The Daiichi Sankyo Managed Markets team is honored to represent this widely recognized symbol of quality from the NCQA for our Under Pressure program."

With a focus on improving quality of care, the Under Pressure initiative was launched in 2006 to foster partnerships between leading managed care organizations and the healthcare providers in charge of patient care. The patient is encouraged to be more actively involved in the management of their cardiovascular health by emphasizing the key elements necessary to live with hypertension including diet, exercise and medication. Health plans drive the initiative by inviting appropriate plan members to participate in the campaign. Once patients opt-in, they receive regular educational mailings including an innovative DVD, and are directed to a program Web site featuring articles, which reinforce the educational mailings. Earlier this year, Daiichi Sankyo announced a culturally competent version of the Under Pressure initiative designed for African-Americans wit
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of the American Society of Hematology
2. Ranbaxy to Bring in Daiichi Sankyo as Majority Partner; Strategic Combination Creates Innovator and Generic Pharma Powerhouse
3. Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel
4. Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize
5. Travel Nurse Across America Awarded Certification From The Joint Commission
6. Dr. Ben Berkhout awarded Retrovirology Prize for contribution to HIV research
7. Perot Systems Awarded Contract Extension By Daughters of Charity
8. SpectraScience Awarded U.S. Patent 7,459,696 for its Unique Methods of Calibrating Spectral Data
9. Jefferson researcher awarded NIH grant
10. Perot Systems Awarded Contract to Implement Health Information System in Kingdom of Jordan
11. Biocept Awarded Accreditation by the College of American Pathologists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)... , , SATURDAY, Dec. 5 (HealthDay News) -- ...d asthma can have bad reactions to certain holiday...ent sneezing and wheezing, according to the Americ...I). , Those who are allergic to live evergreens ma...oth live and artificial trees can trigger symptoms...
(Date:12/5/2009)Wind Turbines are popping up in the most unusual places, and to do everything from growing mushrooms, making wine to keeping prisoners in jail! , (PRWEB) December 5, 2009 -- W
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
(Date:12/4/2009)ANAHEIM, Calif., Dec. 4 Pamela Bowen, Chief Information Officer at Crescent Healthcare, was selected as a finalist for the "Chief Innovation Officer" Appy Award for transforming Crescent,s business w
(Date:12/4/2009)Working with mice, scientists at Johns Hopkins publishing in the December issue of Neoplasia have shown that a protein made by a gene called "Twist" may be the proverbial red flag that can accuratel
Breaking Medicine News(10 mins):Health News:Keep Asthma, Allergies at Bay for the Holidays 2Health News:Distributor Announces New Applications for Wind Turbines 2Health News:Distributor Announces New Applications for Wind Turbines 3Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3
...arguments by critics, a University of Utah-led stu...e in Oregon and the Netherlands did not result in ...rly, poor, women, minorities, uninsured, minors, c...ide at elevated rates. , Fears about the impact ...
...f., Sept. 26 AARP asks,Governor Schwarzenegger to... children currently enrolled in the State Children...e of Representatives passed a bill,which would exp...xpand the program too much. In a letter to the ad...
...exclusive North American rights to bepotastine for...RVINE, Calif., Sept. 26 ISTA,Pharmaceuticals, Inc...d,exclusive North American rights to nasal dosage ...ve North American rights,to ophthalmic allergy app...
..., Sept. 26 While the fall season has,officially b... parasites,lingers with the season,s warm weather....animal health news, offers pet owners these facts ...ronments and feed on the blood of their hosts....
...on of no causal link disputes its own data while s... spotlight conflicts of interest, NIXA, Mo., Sept...hat a CDC study of only 1047 participants, low,com... public. They question how such a poor quality stu...
...t antibody explains why even ,matched, organs get ...y News) -- Researchers say a newly discovered immu...ections and may explain why otherwise well-matched...author and assistant professor of internal medicin...
Other Medicine News:Health News:Doctor-aided suicide: No slippery slope 2Health News:Doctor-aided suicide: No slippery slope 3Health News:Doctor-aided suicide: No slippery slope 4Health News:AARP Calls on Governor Schwarzenegger to Discourage Veto of SCHIP Expansion Bill 2Health News:ISTA Pharmaceuticals Expands Its Pipeline in Allergy Treatments 2Health News:ISTA Pharmaceuticals Expands Its Pipeline in Allergy Treatments 3Health News:ISTA Pharmaceuticals Expands Its Pipeline in Allergy Treatments 4Health News:ISTA Pharmaceuticals Expands Its Pipeline in Allergy Treatments 5Health News:Summer Temperatures Linger, Extend Threat of Parasites 2Health News:CDC Study Links Thimerosal in Vaccines to Motor/Phonic Tics and Deficits in Attention, Behavior Control, Verbal IQ 2Health News:Scientists Spot Key to Kidney Transplant Success 2Health News:Scientists Spot Key to Kidney Transplant Success 3Health News:Scientists Spot Key to Kidney Transplant Success 4
(Date:12/4/2009)DURHAM, N.C., Dec. 4 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) today announced that the first patient has been enrolled in the company,s Phase II-b, dose escalation, clinical trial in S
(Date:12/4/2009)WASHINGTON, Dec. 4 Chemistry World recently highlighted a new report published by the Pharmaceutical Research and Manufacturers of America ( PhRMA ) that identifies 97 new drugs and vaccines in
(Date:12/4/2009)SAN DIEGO, Calif., Dec. 4 Suneva Medical, a privately-held aesthetic medical device company, today announced the appointment of Philip Ranker as Vice President and Chief Financial Officer. In this r
Breaking Medicine Technology:Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland 2U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4National Greatness Contest Winners Announced 58136 1National Greatness Contest Winners Announced 58136 2National Greatness Contest Winners Announced 58136 3MedShape Solutions Inc Announces First FDA cleared Shape Memory PEEK Device 3B Closing of 2410M Equity Offering 14230 1MedShape Solutions Inc Announces First FDA cleared Shape Memory PEEK Device 3B Closing of 2410M Equity Offering 14230 2Global Med Technologies 28R 29 Signs Binding LOI With European Company for Breakthrough Transfusion Safety RFID Product 14225 1Global Med Technologies 28R 29 Signs Binding LOI With European Company for Breakthrough Transfusion Safety RFID Product 14225 2Global Med Technologies 28R 29 Signs Binding LOI With European Company for Breakthrough Transfusion Safety RFID Product 14225 3Global Med Technologies 28R 29 Signs Binding LOI With European Company for Breakthrough Transfusion Safety RFID Product 14225 4Global Med Technologies 28R 29 Signs Binding LOI With European Company for Breakthrough Transfusion Safety RFID Product 14225 5
...-Dose Protection Observed Prior to or Up to 24 Hou...y 24, 2007 /PRNewswire/ -- Targanta,Therapeutics C...nt,study demonstrating oritavancin as a potential ...s, the bacterium which causes anthrax,an acute in...etic,lipoglycopeptide antibiotic for the treatment...
...EY HEIGHTS, N.J.--(BUSINESS WIRE)--May 24, 2007 - ...AQ: CYCCP) announced today,that it will report res...abine (CYC682), a novel orally-available nucleosid...yelodysplastic syndromes,(MDS), at the American So... at McCormick Place in Chicago. Details of the pre...
Other Medicine Technology:Targanta Study Shows Oritavancin Treatment Effective in a Mouse,Model of Anthrax 2Targanta Study Shows Oritavancin Treatment Effective in a Mouse,Model of Anthrax 3Targanta Study Shows Oritavancin Treatment Effective in a Mouse,Model of Anthrax 4Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study,Results at the American Society of Clinical Oncology Annual Meeting 2Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study,Results at the American Society of Clinical Oncology Annual Meeting 3
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
Medicine Products: